Skip to main content
Fig. 3 | Journal of Translational Medicine

Fig. 3

From: Biofluid quantification of TWEAK/Fn14 axis in combination with a selected biomarker panel improves assessment of prostate cancer aggressiveness

Fig. 3

Chord diagram showing differences in correlations between variables across individuals showing differential ISUP GG risk: low-risk ISUP GG (group I and II) and high-risk ISUP GG (group III, IV and V). Segments in circles indicate variables analyzed (see below for abbreviations employed), chords linking variables indicate significant correlations (at least p < 0.05) according to Spearman rank correlations, while chord thickness is directly proportional to correlation coefficient. For clarity, only positive correlations are shown. TEST testosterone, CREAT creatinine, HOMA-IR homeostatic model assessment for insulin resistance, HbA1c hemoglobin A1c, HDL high-density lipoprotein, LDL low-density lipoprotein, CHOL cholesterol, AST aspartate aminotransferase, ALT alanine aminotransferase, GGT gamma glutamyltransferase, PSA prostate-specific antigen, TWEAK tumor necrosis factor-like weak inducer of apoptosis, CD163 cluster of differentiation 163, Fn14 fibroblast growth factor-inducible 14, CXCL5 C-X-C motif chemokine 5, CCL7 chemokine (C-C motif) ligand 7, CXCR2 C-X-C motif chemokine receptor 2, CCR3 C-C chemokine receptor type 3, KLK2 kallikrenin-2 gene, KLK3 kallikrenin-3 gene

Back to article page